05/29/2026
In this clip, Dr. Shannon MacDonald discusses the ongoing Radiotherapy Comparative Effectiveness (RADCOMP) trial, a randomized study directly comparing proton therapy and traditional photon radiation for patients with locally advanced breast cancer who are at higher risk for heart disease.
Breast cancer is the most common cancer diagnosis in the U.S., with an estimated 320,000 individuals expected to be diagnosed in 2025. Locally advanced breast cancer occurs when the cancer has spread beyond the breast tissue but remains confined to nearby lymph nodes or the chest wall. Standard treatment for these patients often includes surgery followed by external-beam radiation therapy, which plays a critical role in preventing cancer recurrence and extending survival.
She explains the trial’s focus on long-term patient outcomes and quality of life — an effort that requires significant time, research, and funding to fully evaluate.
RADCOMP is the largest study to date comparing proton and photon therapy, with additional long-term health and quality-of-life data expected in 2028 and 2032.
To learn more about the trial, visit the link in our bio to watch the full episode: “Photon vs. Proton Therapy for Breast Cancer: The RADCOMP Trial with Dr. Shannon MacDonald.”